Providence, Rhode Island 02903


This study evaluates addition of Vincristine Sulfate Liposome Injection (Marqibo®) to the standard regimen of Bendamustine and Rituximab in adult patients with indolent B-cell lymphoma. This is a dose-escalation study.

Study summary:

Bendamustine-rituximab is a standard chemotherapy regimen for treatment of many indolent B-cell lymphomas, but most patients experience a recurrence of the lymphoma. Vincristine sulfate has been a traditional component of chemotherapy regimens in non-Hodgkin lymphoma and it is possible that adding it to the bendamustine-rituximab regimen might provide a better quality of remissions or longer duration of remissions with acceptable toxicity. This is a phase 1, single-center, open-label, single-arm trial in patients with indolent B-cell non-Hodgkin lymphoma otherwise appropriate for bendamustine-rituximab as initial or subsequent line of therapy. Patients will receive the of rituximab and bendamustine in combination with escalating doses of vincristine sulfate liposome injection (Marqibo®). The objective of this study is to assess safety of this combination by establishing the maximum tolerated dose of vincristine sulfate liposome injection (Marqibo®) in the combination.


Inclusion Criteria: - Histologically confirmed indolent B-cell non-Hodgkin lymphoma. - Radiological measurable disease. - Previous treatment for lymphoma is allowed, with the exception of use of bendamustine within 6 months or any prior use of vincristine sulfate liposome injection - Eastern Cooperative Oncology Group performance status 0 or 1; - Life expectancy of at least 6 months; - Adequate organ and marrow function; - Women of child-bearing potential and men must agree to use adequate contraception. - Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - History of allergic reactions attributed to any drug used in the study. - Any lymphoma-directed therapy within 4 weeks. - Any prior treatment with vincristine sulfate liposome injection. - Prior treatment with bendamustine or vincristine sulfate within 180 days of enrollment. - Patients who are receiving any other investigational agents with the exception of endocrine therapy for breast or prostate cancer. - Central nervous system involvement. - Peripheral sensory or motor neuropathy. - History of a demyelinating condition. - Positive test for the Human Anti-Chimeric Antibody (HACA). - Patients receiving any medications or substances that are strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzyme are ineligible. - Uncontrolled intercurrent illness. - Prisoners. - Pregnant or breast-feeding women. - Known Human Immunodeficiency Virus (HIV) or active Hepatitis B infection - Any prior or active cancer, which in the opinion of the investigator would preclude safe participation in this study.



Primary Contact:

Principal Investigator
Adam J Olszewski, MD
Rhode Island Hospital

Helena Lau, MSPH
Phone: 401-863-3000

Backup Contact:


Location Contact:

Providence, Rhode Island 02903
United States

Helena Lau, MSPH
Phone: 401-863-3000

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.